Skip to main content
CRVSCorvus Pharmaceuticals, Inc.Sell4.7·$9.38

Corvus Pharmaceuticals (CRVS) Q2 2026 earnings — TrendMatrix coverage

MISS · WIDER LOSS-13.4% vs estimateEPS -$0.19 vs -$0.17 estCurrent verdict Sell 4.7/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Adjusted EPS
-$0.19
Estimate
-$0.17
Surprise
-13.4%
Score today
4.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Corvus Pharmaceuticals (CRVS) reported a wider loss than forecast — adjusted EPS of -$0.19 against the -$0.17 estimate (a 13.4% shortfall).

Current read · as of 2026-10-14

Where TrendMatrix's rating stands now

TrendMatrix currently rates CRVS Sell at 4.7/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -13.4% surprise compares with a -3.3% four-quarter average. Next scheduled report: 2026-11-03.

What argues against it

  • Concentration risk — Pipeline: soquelitinib
  • Concentration risk — Supplier: mupadolimab manufacturer
  • DATA_ISSUE: analyst_target_implausible (raw $33.14 vs price $9.38 — ratio 3.5×). Rejected, falling back to technical TP.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$9.38
Price target
$13.19
Stop
$8.93
Upside to target
+40.6%

Risk check: RSI 16 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.

Healthcare context

CRVS at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$791.6M
P/E (fwd)
-8.8
52-week range
$6.39–$26.95
Off 52-week high
65.2%
RSI (14)
16
Volume vs avg
0.74×
Score today
4.7/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › CRVS › Earnings › Q2 2026 earnings